GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » Beta

Coya Therapeutics (Coya Therapeutics) Beta : N/A (As of Jun. 02, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-02), Coya Therapeutics's Beta is Not available.


Coya Therapeutics Beta Historical Data

The historical data trend for Coya Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coya Therapeutics Beta Chart

Coya Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beta
- - - -

Coya Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coya Therapeutics's Beta

For the Biotechnology subindustry, Coya Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coya Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's Beta falls into.



Coya Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Coya Therapeutics  (NAS:COYA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Coya Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Coya Therapeutics (Coya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Executives
Dieter Weinand director C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Fred Grossman officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Goldstein Dov A Md director
Adrian Hepner officer: Chief Medical Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
David S Snyder officer: Chief Financial Officer ONE SCIENCE COURT, MADISON WI 53711
Hideki Garren director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman director, 10 percent owner, officer: Chief Executive Officer C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee director C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc 10 percent owner 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057

Coya Therapeutics (Coya Therapeutics) Headlines

From GuruFocus

Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

By Business Wire Business Wire 06-12-2023